Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02302339 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)

Study Title
A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma (NCT02302339)

Trial Description
This study will examine the effectiveness and safety of glembatumumab vedotin (also known as CDX-011 or CR011-vcMMAE) in patients with advanced melanoma. This trial is sponsored by Celldex Therapeutics. [1]

Study Data

  • Condition: Melanoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 60
  • Start: November 2014
  • Estimated Primary Completion: July 2016
  • Last verified: June 2015

Study Schematic 

NCT02302339 (CLINICAL TRIAL / GLEMBATUMUMAB VEDOTIN / CDX-011 / CR011-VCMMAE)


Last Editorial review: July 28, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar